BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
BioRestorative Therapies, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$1.60+0.06 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $28.36M
- P/E (TTM)
- –
- Dividend yield
- –
BioRestorative Therapies, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $11.87K | $0 | $0 | $300.00K | – | $0 | $230.70K | $69.30K | – | – | – | – | 51.2% | – |
| Royalty [Member] | $11.30K | $19.60K | $11.80K | $3.30K | $25.00K | $43.30K | $2.90K | $19.80K | $35.00K | $19.30K | $30.70K | $64.50K | 48.8% | -54.8% |
By region
From the segment and revenue-disaggregation notes of BioRestorative Therapies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.